4,065 Shares in Insulet Corporation $PODD Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. acquired a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, Holdings Channel reports. The institutional investor acquired 4,065 shares of the medical instruments supplier’s stock, valued at approximately $619,000.

Several other large investors have also made changes to their positions in the business. Trust Asset Management LLC bought a new stake in Insulet during the 2nd quarter valued at approximately $119,000. Tema ETFs LLC increased its position in Insulet by 7.6% in the 2nd quarter. Tema ETFs LLC now owns 4,147 shares of the medical instruments supplier’s stock worth $631,000 after buying an additional 294 shares during the period. Generali Investments Management Co LLC increased its position in Insulet by 60.5% in the 2nd quarter. Generali Investments Management Co LLC now owns 2,738 shares of the medical instruments supplier’s stock worth $417,000 after buying an additional 1,032 shares during the period. Handelsbanken Fonder AB lifted its holdings in shares of Insulet by 6.4% during the second quarter. Handelsbanken Fonder AB now owns 23,216 shares of the medical instruments supplier’s stock worth $3,535,000 after buying an additional 1,400 shares during the last quarter. Finally, Sax Wealth Advisors LLC lifted its holdings in shares of Insulet by 56.4% during the second quarter. Sax Wealth Advisors LLC now owns 3,751 shares of the medical instruments supplier’s stock worth $571,000 after buying an additional 1,353 shares during the last quarter.

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.36% of the company’s stock.

Insulet Stock Performance

PODD opened at $139.70 on Tuesday. The stock’s 50 day simple moving average is $154.96 and its 200-day simple moving average is $187.34. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a market cap of $9.69 billion, a PE ratio of 26.11, a P/E/G ratio of 1.13 and a beta of 1.10. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same period last year, the business earned $1.17 earnings per share. Insulet’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts forecast that Insulet Corporation will post 6.51 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PODD. Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Insulet in a report on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 price target for the company. The Goldman Sachs Group restated a “buy” rating and issued a $205.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Finally, Leerink Partners lowered shares of Insulet from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $247.00 to $145.00 in a research report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $195.40.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest quarterly results exceeded expectations, with earnings of $1.66 per share versus the $1.47 consensus estimate and revenue of $801.7 million versus $787.4 million expected. Revenue increased 23.5% year over year. Why Insulet PODD Stock Is Down Today
• Positive Sentiment: Insulet insiders have predominantly purchased shares during the past six months, including sizable purchases by CEO Ashley McEvoy and other directors. Such buying may signal management confidence following the stock’s decline. Why Insulet PODD Stock Is Down Today
• Neutral Sentiment: Analyst coverage remains generally favorable, with recent Buy-equivalent ratings and a reported median price target of $219.50. However, some recent targets are lower, including $172 from Citigroup and $180 from Evercore ISI, reflecting more cautious near-term expectations. Why Insulet PODD Stock Is Down Today
• Negative Sentiment: The main fundamental concern is Insulet’s softer forward outlook. Lower full-year Omnipod growth guidance and a weaker third-quarter forecast suggest slowing U.S. momentum, overshadowing the earnings and revenue beat. Why Insulet PODD Stock Is Down Today
• Negative Sentiment: Multiple law firms are promoting a securities class action against Insulet and certain executives, alleging investors were harmed by disclosures concerning defective Omnipod manufacturing controls. The allegations have not been proven, but the litigation adds legal, regulatory and reputational risk. The reported lead-plaintiff deadline is August 31, 2026. Insulet Class Action Announcement
• Negative Sentiment: Earlier disclosure of a voluntary correction involving certain Omnipod products, reportedly affecting approximately 7 million Pods and potentially causing insulin under-delivery, continues to raise concerns about manufacturing execution and future costs. Why Insulet PODD Stock Is Down Today

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.